102 results about "Antigen antibody binding" patented technology

The invention discloses a diluent enabling stability for acridinium ester antigen-antibody conjugate. The diluent is prepared by adding a carbohydrate, polyalcohol, amino acids, a protein stabilizer, a chelating agent, a surfactant, a preservative and an additive into a buffer solution; the diluent prepared by the invention overcomes the defect that acridinium ester is unstable and easily hydrolyzes in the buffer solution, can protect the acridinium ester antigen-antibody conjugate to improve its stability and prolong its service life, and also can be fully used in in-vivo diagnostic kits.

A system and method for testing for the presence of antigens in food stuffs permits a user to test food products for the presence of antigens for a given food allergy that the user may have. The system comprises two main components, a base station and a test well. The user places a sample of food into the test well. A macerator homogenizes the food in the test well. Antibodies to a particular antigen are bound to an antigen detector in the test well. The base station includes a cartridge dock which powers the macerator and the antigen detector. Antigen-antibody binding provides a change detectable by the detector, which signals the base station of the presence of a threshold degree of antigen-antibody binding and alerts the user of the presence of the antigen, such as by a visual or audible indicator.

The invention relates to a rolling circle amplification-based colorimetric assay method for target nucleic acids or proteins. The method mainly utilizes the hybridization between nucleic acids and antigen-antibody binding to indirectly fix the target nucleic acids or proteins to be assayed onto magnetic beads, rolling circles are added, a rolling circle primer on hybrid is utilized to carry out constant-temperature rolling circle amplification, and finally, the chromogenic reaction of nanogold is utilized to assay constant-temperature amplified macromolecular product in order to achieve the purpose of relatively assaying the target nucleic acids and proteins. By integrating rolling circle amplification and the chromogenic reaction of nanogold, the method not only amplifies a large quantity of micro-sample signals, but also realizes the rapid, visual assay of results, avoids the usage of a PCR (Polymerase Chain Reaction) instrument and other expensive instruments, and decreases the requirement on the experimental hardware condition. The method is expected to be applied in bedside rapid diagnosis and the field rapid assay of microorganisms in food safety and the environment.

This invention provides one dog rabies virus antigen glue gold immune chromatography test paper and its process, which comprises the following steps: according to antigen antibody immune combination basic principle to label the sheep IgG by glue gold label covering on the glass fiber film as combination pad; covering the purification rabies virus antigen and gene engineer expressed antigen and rabit IgG covering on the NC film as test line and quality control line; when testing the antibody, forming antibody combination to expose red band.

The invention relates to a chimeric antigen receptor based on CD20, and applications thereof, and more specifically relates to a cell technology construction method of chimeric antigen receptor T (CAR-T) taking tumor specific target spot CD20 as a base, and applications of the chimeric antigen receptor T in treatment of tumor. The chimeric antigen receptor T is composed of an antigen binding domain, a transmembrane domain, a costimulatory signal transduction region, and a CD3 zeta signal transduction domine via series connection; wherein the antigen binding domain is used for binding tumor surface antigens, and the tumor surface antigen is CD20. According to applications, specific gene modification of single-chain antibody of tumor surface antigen CD20 is carried out, the modified antibody is capable of increasing antigen-antibody binding force, mutation is not easily caused. Compared with other chimeric antigen receptors and other tumor antigens, the chimeric antigen receptor possesses following advantages: the effect is better, target spot expression quantity is higher, immune effect on CAR-T cells is improved, and treatment effect of CAR-T cells is improved.

The invention relates to colloidal gold test paper for rapidly detecting an antibody of a porcine reproductive and respiratory syndrome virus (PRRSV). The test paper is characterized in that: the test paper is composed of a sample pad, a combination pad, a nitrocellulose membrane and an absorption pad which are sequentially attached to a nonabsorbent supporting sheet, wherein the combination pad is covered by PRRSVNsp9 proteins marked by colloidal gold; and the nitrocellulose membrane is respectively covered by a detection line T line composed of staphylococcus proteins A (SPA) and a quality control line C line composed of PRRSVNsp9 monoclonal antibodies 2D6. According to the invention, by utilizing an immunological principle that antigens and antibodies can be specially combined, the antigen marked by the colloidal gold is combined with the corresponding antibody and the conjugate of the antigen and the antibody is combined with the SPA to form an antigen-antibody-SPA conjugate, so as to form a color reaction on the nitrocellulose membrane (NC membrane) to be observed by naked eyes. The test paper provided by the invention has the characteristics of simplicity, fastness, sensitivity, good specificity and the like. And the price is low, so that the test paper is applicable to basically or clinically detecting the antibody of the porcine reproductive and respiratory syndrome virus. The test paper has the obvious advantages of strong specificity, high flexibility, simplicity in operation and fastness in diagnosis, and can be used for rapidly diagnosing the porcine reproductive and respiratory syndrome virus.

The invention discloses a MOS-pipe-based double-grid-regulation ultra-high-sensitivity biosensor, which is suitable for a series of early-stage tumour detection. The sensor is made from an SOI sheet,and a unique double-grid control structure is formed through ion implantation. The sensor is made via ultraviolet lithography combined with an NLD etching method and can detect a trace amount of a tumour marker immediately without labeling. Compared with a common sensor used for detecting current or conductance, the sensor can detect change of capacitance in a channel in an antigen-antibody combination process. A detection method related in the invention is stable and good in interference immunity, and can meet the requirements of detection range and sensitivity, has extremely outstanding performance particularly with respect to detection sensitivity, and can detect a sample with the lowest concentration in a range of 1 fg / ml-1 ng / ml.

The invention relates to a detection method for solid phase competition ELISA (Enzyme Linked Immuno Sorbent Assay) of foot and mouth disease, belonging to the technical field of serology diagnosis of animal epidemic diseases. The detection method comprises the following steps of: bonding a foot and mouth disease antibody on an ELISA plate through a coating technology; then firmly binding the foot and mouth disease antibody into the ELISA plate through an antigen-antibody binding reaction; processing and drying the foot and mouth disease antibody with a stabilizing agent and packaging the foot and mouth disease antibody in vacuum; and finally placing the foot and mouth disease antibody at low temperature for storage in a long period of time. When the foot and mouth disease antibody is necessary to detect, the ELISA plate can be directly used for experiments and can ensure that the experiment process is simple and saves time.

A method for detecting high antigen concentration is disclosed. The method enables the mobile-phase antibody, in the presence of excessive amount of antigen, to form the antibody-antigen-antibody sandwich with the immobilized solid-phase antibody effectively in a rapid lateral flow chromatographic immunoassay. The mobile-phase and / or immobilized solid-phase antibody are treated with soluble coatings to generate a delaying mechanism, so that antigen-antibody binding occurs only when both phases of antibodies and antigen are in very close proximity. A user friendly immunoassay device with a sample over-flow mechanism also facilitates such antigen-antibody binding.

The invention provides a method for simply and quickly detecting hoptoglobin in serum, namely an immunoturbidimetry, and a detecting kit thereof. The method is a detecting method designed by using the principle that the hoptoglobin is a human protein, has antigenicity and generates cohesion after combining with an antigen antibody. The hoptoglobin in the serum sample is combined with adequate specific antibody in the agent to form an insoluble immune complex; the change of the absorbance of the reaction solution is relevant to the content of the hoptoglobin in the serum sample. The method for detecting the hoptoglobin in the serum and the detecting kit in the invention have the advantages that: the serum sample is not subjected with special treatment, and can be ordinarily detected on an automatic biochemistry analyzer; the result directly reflects the true protein content of the hoptoglobin in the serum sample; therefore, the invention is used for clinic detection.

The invention relates to a device for performing binding assays. In particular, the invention relates to a centrifugal device for performing such assays. The invention also relates to a method of performing binding assays involving antigen-antibody binding, nucleic acid hybridization, or receptor-ligand interaction.

The invention relates to a kit for high-sensitivity detection on proteoglycan and a preparation method of the kit. The kit comprises carboxyl graphene coupled with a monoclonal antibody and / or carboxyl graphene coupled with a polyclonal antibody, fluorescent proteins with high-positive charges, and a buffering solution. The invention further relates to a preparation method of the kit. According to the kit for high-sensitivity detection on the proteoglycan, an elisa plate is not needed to be adsorbed and wrapped by an antibody, and such complicated steps of washing antigen and antibody combination and the like are eliminated; and furthermore, quick detection and analysis on target proteoglycan in a homogeneous system can be realized, and the sensitivity is high.

The invention discloses a preparation method of a novel cytokine fusion protein-chemokine interferon inducible protein 10 single-chain antibody (IP10-scFv). The method comprises the steps of: S1. synthesizing a human IP10 extracellular terminal gene; S2. utilizing a recombinant phage antibody system to construct the single-chain antibody of an anti-epidermal growth factor receptor mutant III (EGFRvIII); S3. conducting optimization synthesis on a (Gly4Ser)3 flexible joint; S4. cloning IP10 and the anti-EGFRvIII single-chain antibody into an eukaryotic expression vector, and conducting connection through the optimized (Gly4Ser)3 flexible joint, thus obtaining an IP10-scFv gene; and S5. subjecting the gene to high expression in Escherichia coli, thus obtaining IP10-scFv with biological activity. The IP10-scFv provided in the invention has a higher antigen-antibody binding rate, can reduce the dosage of IP10 clinically and reduce the toxic and side effects, and further can reduce the adoptive input amount of glioma specific cytotoxic T lymphocyte (CTL) and increase the activity of CTL.

One mycobacterium tuberculosis antigen detective method in tuberculosis bacilli solution, including the following steps: (a) Choice and prepare TB-specific antigen that can be detect by the antigen-antibody binding reactions in various body fluids; (b) Prepare of confrontation and strains of TB-specific antigen monoclonal antibody; (C) Prepare TB detection reagent kit of specific antigen secreted; (d) Use the above-mentioned antibody and antigen detection kit for tuberculosis. Take these steps and reach high rate of the test and correct testing purposes.

The invention relates to a mimic eptitope peptide of BAFF-R and a DNA coding the peptide and the application of the mimic eptitope peptide in the preparation of antitumor bacterins and drugs. The mimic eptitope of 7 amino acids of BAF-R is a mimic eptitope of molecule BAFF-R with high affinity with a monoclonal antibody of BAFF-R, and is obtained through selection from a phage random display 7-peptide bank with a monoclonal antibody of BAFF-R as the antigen, wherein the sequence of the amino acids is Gly Tyr Thr Arg Trp Gly Cys. The 7-amino-acid mimic eptitope can also be used to construct a poly-peptide vaccine. The clonal inhibition rates of the phage display peptide provided by the invention are all more than 50 percent, and can specifically inhibit the combination between antibody and antigen for a larger extent, greatly improve the proliferation of mouse spleen lymphocytes without adjuvant, the mimic antigen is good in immunogenicity, as illustrated by the induced cell immune response after mice are vaccinated with the mimic antigen.

The present invention relates to a biomarker set for diagnosing breast cancer comprising two or more protein markers of: apolipoprotein C1, apolipoprotein (a), neural cell adhesion molecule L1-like protein, carbonic anhydrase 1, and fibronectin; a method for detecting the biomarker set in a blood sample through a multiple reaction monitoring; a kit for diagnosing breast cancer comprising antibodies specific to each of the proteins of the biomarker set; and a method for detecting proteins of the marker set in a blood sample through an antigen-antibody binding reaction. The method for detecting the protein marker set in a blood sample by the MRM method or antigen-antibody binding reaction and the diagnostic kit can provide very high accuracy and sensitivity in comparison with the diagnosis method using a single marker and can very conveniently diagnose breast cancer using blood from patients, thereby being effectively used for early diagnosis of breast cancer.

The present invention discloses a blood type detection method based on a membrane structure. According to the method, a filtration membrane allowing a single red blood cell to pass through is selected as a core material, blood type antibodies are bound to the filtration membrane, a water absorption material is surrounding the periphery of the filtration membrane, red blood cells with a certain concentration are added on the filtration membrane surface in a dropwise manner during detecting, rinsing is performed with a rinsing liquid, the red blood cells with no antigen-antibody binding exude along with the rinsing liquid, the red blood cells with the antigen-antibody binding are remained on the membrane surface so as to form the visible red clumps, and an operator can judge the result according to whether the red blood cells form the visible red clumps on the filtration membrane so as to determine the blood type of red blood cells. The method of the present invention has beneficial effects of short detection time and objective result.

The invention provides a novel serology biomarker GSK3beta detection method for cognitive impairment of a diabetic. The method comprises an enzyme activity assay method and a relative quantification dot-blot method. According to the enzyme activity assay method, a GSK-3beta enzyme activity assay kit of GENMED is applied; GSK-3beta phosphorylation is performed under the suppression of GSK-3alpha; along with oxidation reaction of reduced form of nicotinamide-adenine dinucleotid (NADH), a pyruvate kinase and lactic dehydrogenase continuous circulation method reaction system adopts the spectrophotometric method to measure the peak value change after oxidization so as to reflect GSK 3beta activity in a sample. The dot-blot method transfers blood platelet protein to an NC film according to the antigen and antibody fixation reaction principle and then utilizes antibody to perform detection. The novel serology biomarker GSK3beta detection method is used for studying GSK-3beta protein and enzyme activity expression in the diabetic blood and is expected to become a serology biomarker for early diagnosis of Alzheimer's disease (AD).

The invention relates to a super sensitivity fluorescence biosensor, for using magnetic practical to load antibodies and capture antigens, using water soluble conjugated polyelectrolyte to induce fluorescence amplification to check Escherichia coli O157: H7, which first utilizes magnetic particles to capture Escherichia coli O157: H7 antigens, to generate an antigen antibody unity with fluorescence labels; adds water soluble conjugated polyelectrolyte to induce and act with electrostatics, to recognize the super-molecules between the antigen antibody unity and the conjugated polyelectrolyte to form a super-molecule fluorescence composite system; exciting the fluorescence composite via the light or electricity of the conjugated polyelectrolyte, to induce the super fluorescence amplification of thousands and millions level of the prior fluorescence label signals, thereby forming a super sensitivity fluorescence biosensor. The biosensor system is based on the fluorescence sensitivity raising and efficiency raising effect of water soluble conjugated polyelectrolyte, which can be applied for fast super sensitivity detection on acute infectious disease as Escherichia coli O157: H7.

The invention provides a processing method for low-allergenic crabs based on directional modification for key amino acids and relates to the field of food processing. The processing method comprises the following steps: salting pretreatment of crabs; directional modification for key amino acids; product packaging. After crabs are cooked in different ways, crude proteins are extracted; SDS-PAGE electrophoresis and Dot Blot are adopted for analyzing the crude proteins after thermal processing at different degrees; the allergenicity of crabs under different processing modes is judged according tothe degree of immune binding on the basis of taking binding activity of a rabbit anti-TM polyclonal antibody as an index; the processing mode of low-allergenic crabs is screened. Simple antigen antibody combination reaction is utilized to confirm the change in allergenicity after crab allergen is subjected to different thermal processing; the processing method for low-allergenic crabs based on directional modification for key amino acids is screened; the process is simple, the operability is high and the processing method is easy for large-scale production.

The present invention relates to a beef-specific age determination marker containing the p21 protein, to a beef-specific age determination kit containing an antibody which is specifically bound to the p21 protein, and to a method which involves detecting the p21 protein through an antigen-antibody binding reaction using an antibody which is specifically bound to the p21 protein serving as a beef-specific age determination marker in the muscle tissue of beef, so as to determine the age of the beef. According to the present invention, the p21 protein is significantly greatly expressed in the muscle tissue of beef, the age of which is lower than 30 months, and is hardly expressed in the muscle tissue of beef, the age of which is greater than 30 months, and thus can be valuably used as a beef-specific age determination marker.

The invention discloses a CAR-T cell preparation for treating breast cancer and a preparation method thereof. The preparation disclosed by the invention is prepared from CAR-T cells, human serum albumin, IL-6 receptor antagonist Tocilizumab and normal saline in a certain proportion. The chimeric antigen receptor(CAR) prepared by the method disclosed by the invention is mainly composed of an antigen antibody binding region, a transmembrane region, a CD3zeta intracellular signal region and a co-stimulatory signal transmitting region. According to the CAR-T cell preparation for treating breast cancer disclosed by the invention, the CAR-T cells with chimeric breast cancer cell antigen receptors are used for treating breast cancer, the treatment effect is obvious, and the invention fundamentally provides a method for treating breast cancer.

The invention discloses a magnetic particles chemiluminescence detection method. The method combines with the magnetic separation technology, the chemiluminescence technology, and the immunoassay technology. The method fully utilizes the rapid and easy automation performance of the magnetic separation technology, the high sensitivity performance of the chemiluminescence technology, and the specificity of the immunoassay, and exhibits an irreplaceable role in the field of biological analysis. Compared with a previous membrane strip immunoassay method and enzyme-linked immunosorbent assay method, the method has greatly improved the detection sensitivity, the detection range, the detection time, and the automation operation. According to the magnetic particles chemiluminescence detection method, the antigen-antibody binding surface area is large, and the detection sensitivity is improved by increasing the binding amount of the antigen-antibody; the reaction speed is fast, and the antigen-antibody can be rapidly captured; the combined phase and free phase are easy to separate, which can improve the detection accuracy; and the alkaline phosphatase luminescence system has good stability.

The invention relates to a CD117-based chimeric antigen receptor (CAR) and application thereof, in particular to a method for constructing a CRA-T cell technology based on a tumor specific target CD117 and application of the method in anti-tumor therapy. The CAR is formed by connecting an antigen binding domain, a transmembrane domain, a costimulatory signal transduction zone and a CD3 zeta signal transduction domain in series, wherein the antigen binding domain binds to a tumor surface antigen, and the tumor surface antigen is CD117. The CAR provided by the invention is obtained by carrying out specific genetic modification on the tumor surface antigen CD117, and the modified antibody can enable the antigen-antibody binding force to be stronger and is not easy to mutate. Compared with other CARs and other tumor antigens, the CD117-based CRA has better effects and high target expression quantity, thus enhancing the immune effect of CAR-T cells and improving the therapeutic effect of the CAR-T cells.

The invention relates to a human anti-hepatitis B virus surface antibody as well as a preparation method and application thereof. A specific hepatitis B antibody with relatively high affinity activity on hepatitis B virus antigens can be obtained by virtue of antigen-antibody binding activity screening, wherein an amino acid sequence of a light chain variable region of the antibody is shown in SEQ ID No. 1 or SEQ ID No. 2, and an amino acid sequence of a heavy chain variable region of the antibody is shown in SEQ ID No. 3 or SEQ ID No. 4. According to the human anti-hepatitis B virus surface antibody disclosed by the invention, antibody mutation hot spots are analyzed by virtue of a protein molecule modeling technology and are subjected to saturation mutation by taking an amino acid as a unit so as to construct a mutant library and perform biological verification, and thus optimization of the antibody can be achieved. The human anti-hepatitis B virus surface antibody disclosed by the invention can be used for laying a foundation for preventing hepatitis B virus infection and performing treatment research at the same time, so that the human anti-hepatitis B virus surface antibody can be applied to the prevention and treatment of liver diseases caused by hepatitis B virus infection clinically.

A gold-labeling chromatography method for quickly detecting beta-excitant includes reaction of liquid speciment with gold-labelled clenbuterol antibody to obtain antigen-antibody compound, competing with clenbuterol-BSA coupled substance for the compound antibody, and reaction of said antigen-antibody compound or gold labeling antibody with the antibody. Its advantage is high speed.

The invention discloses an ELISA (enzyme-linked immuno sorbent assay) method based on a pH (potential of hydrogen) meter. The ELISA method comprises the following steps of performing antigen-antibody specificity immune reaction in an ELISA plate, capturing the antigen or antibody of the analyzing matter in a sample, introducing the glucose oxidase-glucose biological catalytic reaction, and using the pH meter to measure the pH value of the mixed product solution containing the glucose, wherein the size of the pH value is negatively related with the concentration of the analyzing matter in the sample, so as to complete the ELISA based on the pH meter. The ELISA method has the advantages that the signal is read by the low cost pH meter, so the cost of quantitative analysis is reduced; the response signal of single antigen-antibody bonding reaction is amplified by the micrometer or nanometer immobilized glucose oxidase; while the good specificity of the traditional ELISA method is maintained, the immobilizing amount of the glucose oxidase is increased by the micrometer or nanometer particles; the response signal of the single antigen-antibody specificity bonding reaction is amplified, and the detection sensitivity is improved.

A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.

The invention provides a diluent capable of improving the stability of an acridinium ester antigen-antibody conjugate and reducing the background. The diluent comprises the components of 5 to 7g of Tris-base, 3.5 to 4.0 mL of concentrated hydrochloric acid, 9 to 11 g of polyethylene glycol-6000, 0.95 mL to 1.05 mL of 10% lauryl sodium sulfate, 9.5 mL to 10.5 mL of Tween, 0.8 to 1.0 g of ethylene diamine tetraacetic acid disodium salt, 9 to 11 g of sodium caseinate, 0.95 mL to 1.05 mL of Proclin 300, 9.5 to 10.5 mL of triton X-100, and 1000mL of purified water for an in-vitro diagnostic reagent. The diluent has the advantages that the components are few; polyethylene glycol 6000, sodium dodecyl sulfate, tween and several active agents are mixed for use, meanwhile, a Tris-base buffer solution system is used, and multiple raw materials play a mutual synergistic effect, so that the diluent has a better protection effect on acridinium ester labeled antigens and antibodies, can be stored for a long time, can provide good blocking property and protectiveness for the antibodies, and reduces non-specific reactions; meanwhile, the material cost is saved, the specificity, stability, repeatability and other properties of the reagent are not influenced, and the reagent is suitable for popularization and application.